Vial

MAY 20, 2024

Within each of these, pharmaceutical and biotech sponsors are supported by preclinical and clinical contract research organizations (CROs) in clinical trials across various indications. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030). Their ability to adapt to evolving regulations and industry standards reduces the likelihood of costly setbacks.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

Agency IQ

NOVEMBER 20, 2023

Summary of Product Characteristics and Package Leaflet), recommending that sponsors and regulators “explore the use of electronic media” to provide product information “in the future”. If the ePI is approved by the regulator, then it will be made publicly available in the ePI database.

Production 40

Production Packaging Hospitals Regulations 40

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. In response to this hysteria, regulation was aggressively tightened. Between the technical uncertainty and the horrendous PR, pharmaceutical companies had little interest in adopting molecular farming technologies.

Engineering 87

Engineering Vaccine Production RNA 87

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. In working together, we envision protecting or enhancing 1 billion lives by 2030.

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. million in direct funding and $6.25

Vaccine 52

Vaccine Government International Virus 52

Agency IQ

DECEMBER 15, 2023

The 174 regulations the EPA is currently working on The Environmental Protection Agency has unveiled its Fall 2023 Unified Agenda, which provides a look into the agency’s regulatory agenda for the upcoming year. The expected release dates of the agendas rarely line up exactly with the actual dates when the agency releases the regulation.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

JUNE 16, 2023

Highlights of the EPA’s Unified Agenda for Spring 2023 The Office of Management and Budget has released the Unified Agenda for Spring 2023, which outlines the regulations that agencies expect to release in 2023 and 2024. This information would be used in considering the regulation of asbestos.

Regulations 40

Regulations Compliance Production Science 40